Leveraging this unique resource, we herein sought to (1) elucidate the effects of PD-1 inhibition on primary tumor-infiltrating and circulating immune cell populations in ccRCC and (2) correlate TME and circulating immune cell compositions with response to anti-PD-1 therapy. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.